About: http://data.cimple.eu/news-article/4a47b2a1bbf181969d5ec11f7894a201b06b221541cd39809d7c8971     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • US President Donald Trump is receiving an experimental treatment of synthetic antibodies for Covid-19, his doctor said Friday, and is "fatigued but in good spirits." Trump received a single dose of Regeneron's antibody cocktail, according to a letter issued by White House physician Sean Conley. The treatment is undergoing clinical trials but hasn't received any form of regulatory approval. "He's being evaluated by a team of experts, and together we'll be making recommendations to the President and First Lady in regards to next best steps," Conley said. Trump -- who has repeatedly cast doubt on the seriousness of the pandemic -- first announced in an overnight tweet that he and First Lady Melania Trump, 50, had tested positive and were going into quarantine. Earlier this week, Regeneron announced results from one of its early-stage trials which showed its drug, which is infused intravenously, reduced viral load and recovery time in non-hospitalized Covid-19 patients. "We have begun discussing our findings with regulatory authorities while continuing our ongoing trial," said George Yancopoulos, the company's president and chief scientific officer on Tuesday. The US biotech firm is concurrently running late-stage trials for hospitalized Covid-19 patients and for the drug's potential use as a prophylaxis. Antibodies are infection-fighting proteins made by the immune system that can bind to particular structures on the surfaces of pathogens and prevent them from invading cells. Vaccines work by teaching the body to make its own antibodies, while scientists are also testing ready-made antibodies from the blood of recovered patients, called convalescent plasma. But it is not possible to make convalescent plasma a mass treatment. Researchers can also comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture it at scale. Regeneron's experimental Covid-19 drug, called REGN-COV2, is a combination of two antibodies, referred to as a "cocktail." The idea is it will have a better chance at working if the virus mutates in order to evade the blocking action of a single antibody. Last year, a triple-antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus. ia/ec
schema:headline
  • 'Fatigued' Trump receiving experimental antibodies treatment
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software